{"id":795225,"date":"2024-12-16T16:18:00","date_gmt":"2024-12-16T21:18:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/"},"modified":"2024-12-16T16:18:00","modified_gmt":"2024-12-16T21:18:00","slug":"omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/","title":{"rendered":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference<\/b><\/p>\n<p class=\"bwalignc\"><b><i>Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub<sup>\u2122<\/sup>, a bioinformatics tools platform<\/i><\/b><\/p>\n<p>EMERYVILLE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>OmniAb, Inc. (NASDAQ: OABI) <\/b>today announced that two presentations featuring the Company\u2019s technologies were delivered at the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finformaconnect.com%2Fantibody-engineering-therapeutics%2F&amp;esheet=54166758&amp;newsitemid=20241216917013&amp;lan=en-US&amp;anchor=2024+Antibody+Engineering+%26amp%3B+Therapeutics+Conference&amp;index=1&amp;md5=483455fe43ca43c5b86069b1fef0420d\">2024 Antibody Engineering &amp; Therapeutics Conference<\/a> (AETC) underway in San Diego.<\/p>\n<p>\nIn a presentation titled \u201cBuilding Multispecifics from <i>in vivo<\/i> Derived Antibody Domains and Alternative Scaffolds,\u201d Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from traditional CD3 T cell engagers to next-generation NK cell engagers, facilitated by emerging targets such as NKp46.<\/p>\n<p>\n\u201cOmniAb\u2019s technologies offer significant advantages in multispecifics, including naturally optimized human sequence immune repertoires across multiple host species, a variety of antibody modalities to support novel molecular formats, and artificial intelligence (AI)-augmented single B cell workflows for deep repertoire mining,\u201d said Matt Foehr, Chief Executive Officer of OmniAb. \u201cWe have a strong track record of delivering candidates which lead to clinical-stage and approved bispecifics, where on-target specificity, developability, tunable affinity and broad epitope coverage are all important elements. Leveraging this foundation, our platform offers versatile multi-modality options, providing our partners with the flexibility to execute their campaigns effectively.\u201d<\/p>\n<p>\n\u201cThis case study presentation demonstrates how we discovered developable anti-NKp46 binders with broad epitope coverage and affinities, serving as building blocks for NK cell engager multispecifics. We enhanced high-throughput phenotypic screening with AI-guided next-generation sequencing workflow to explore the vast sequence space and identify high-quality leads, thereby avoiding extensive ex vivo engineering,\u201d added Dr. Abdiche.<\/p>\n<p>\nAt AETC the Company also highlighted OmniHub<sup>\u2122<\/sup>, a high-dimensional unified bioinformatics portal, in a presentation titled \u201cDesign and Implementation of OmniHub<sup>\u2122<\/sup>, A Platform for Bioinformatics Tools Facilitating Antibody Discovery Workflows,\u201d by Swetha Garimalla, Ph.D., Director of Computational Immunology. OmniHub<sup>\u2122<\/sup> is part of OmniAb\u2019s ongoing commitment to enhancing the partner experience with its technologies and services. OmniHub<sup>\u2122<\/sup> enables scalable and secure data transfer, advanced visualization and comprehensive tool access.<\/p>\n<p>\nOmniAb is showcasing its entire technology stack at the 2024 Antibody Engineering &amp; Therapeutics Conference December 15-18 at exhibit booth #300 at the Marriott Marquis San Diego Marina.<\/p>\n<p><b>About OmniAb<sup>\u00ae<\/sup><\/b><\/p>\n<p>\nOmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners\u2019 drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence<sup>\u2122<\/sup> (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.<\/p>\n<p>\nWe believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.<\/p>\n<p>\nOur proprietary transgenic animals, including OmniRat<sup>\u00ae<\/sup>, OmniChicken<sup>\u00ae<\/sup> and OmniMouse<sup>\u00ae<\/sup> have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic<sup>\u00ae<\/sup> and OmniClic<sup>\u00ae<\/sup> are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur<sup>\u2122<\/sup> provides cow-inspired antibodies with unique structural characteristics for challenging targets. Omni<i>dAb<\/i><sup>\u2122<\/sup> is an <i>in vivo<\/i> platform for the discovery of single-domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep<sup>\u2122<\/sup>, which is a suite of <i>in silico<\/i>, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb\u2019s technology and creates opportunities in many important and emerging target classes.<\/p>\n<p>\nOmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics and many others.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.omniab.com&amp;esheet=54166758&amp;newsitemid=20241216917013&amp;lan=en-US&amp;anchor=www.omniab.com&amp;index=2&amp;md5=a194793ec02d294aef5d05009d81ca4d\">www.omniab.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nOmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or continue\u201d and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the expected performance of our technologies and their impact on our partners; and the ability of our technologies to generate antibodies which will progress into the clinic or received marketing approval. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; and other risks described in our prior press releases and filings with the SEC, including under the heading \u201cRisk Factors\u201d in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241216917013\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241216917013\/en\/<\/a><\/span><\/p>\n<p>\nOmniAb, Inc.<br \/>\n<br \/>Neha Singh, Ph. D.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@OmniAb.com\">investors@OmniAb.com<br \/>\n<\/a><br \/>X @OmniAbTech<br \/>\n<br \/>(510) 768-7760<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Other Technology Technology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub\u2122, a bioinformatics tools platform EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company\u2019s technologies were delivered at the 2024 Antibody Engineering &amp; Therapeutics Conference (AETC) underway in San Diego. In a presentation titled \u201cBuilding Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,\u201d Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from traditional CD3 T cell engagers to next-generation NK cell engagers, facilitated by emerging targets such as NKp46. \u201cOmniAb\u2019s technologies offer significant advantages in multispecifics, including &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795225","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub\u2122, a bioinformatics tools platform EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company\u2019s technologies were delivered at the 2024 Antibody Engineering &amp; Therapeutics Conference (AETC) underway in San Diego. In a presentation titled \u201cBuilding Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,\u201d Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from traditional CD3 T cell engagers to next-generation NK cell engagers, facilitated by emerging targets such as NKp46. \u201cOmniAb\u2019s technologies offer significant advantages in multispecifics, including &hellip; Continue reading &quot;OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-16T21:18:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference\",\"datePublished\":\"2024-12-16T21:18:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/\"},\"wordCount\":1044,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/\",\"name\":\"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-16T21:18:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/","og_locale":"en_US","og_type":"article","og_title":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk","og_description":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub\u2122, a bioinformatics tools platform EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company\u2019s technologies were delivered at the 2024 Antibody Engineering &amp; Therapeutics Conference (AETC) underway in San Diego. In a presentation titled \u201cBuilding Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,\u201d Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from traditional CD3 T cell engagers to next-generation NK cell engagers, facilitated by emerging targets such as NKp46. \u201cOmniAb\u2019s technologies offer significant advantages in multispecifics, including &hellip; Continue reading \"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-16T21:18:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference","datePublished":"2024-12-16T21:18:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/"},"wordCount":1044,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/","name":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-16T21:18:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241216917013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-technologies-featured-in-two-presentations-at-the-2024-antibody-engineering-therapeutics-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering &amp; Therapeutics Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795225"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795225\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}